Graybug Vision, Inc. GRAY
We take great care to ensure that the data presented and summarized in this overview for GRAYBUG VISION, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GRAY
View allLatest Institutional Activity in GRAY
Top Purchases
Top Sells
About GRAY
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Insider Transactions at GRAY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,076
+8.53%
|
$10,152
$2.9 P/Share
|
|
Aug 15
2025
|
Sudarshan Hebbar Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,392
+7.79%
|
$8,784
$2.79 P/Share
|
|
Aug 14
2025
|
Sudarshan Hebbar Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,584
+3.22%
|
$3,168
$2.58 P/Share
|
|
Jul 28
2025
|
Kenneth A. Stauderman Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+7.17%
|
$3,000
$3.96 P/Share
|
|
Jul 25
2025
|
Kenneth A. Stauderman Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
1,000
-100.0%
|
$3,000
$3.65 P/Share
|
|
Jul 22
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,500
+2.95%
|
$4,500
$3.77 P/Share
|
|
Jul 21
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,500
+3.04%
|
$4,500
$3.37 P/Share
|
|
Jul 21
2025
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,000
+22.22%
|
$3,000
$3.4 P/Share
|
|
Jul 18
2025
|
Robert N Wilson |
BUY
Open market or private purchase
|
Direct |
4,500
+1.06%
|
$9,000
$2.87 P/Share
|
|
Jul 18
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
2,000
+4.14%
|
$4,000
$2.88 P/Share
|
|
Jul 14
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
6,500
+12.79%
|
$13,000
$2.43 P/Share
|
|
Jul 14
2025
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Indirect |
2,500
+50.0%
|
$5,000
$2.47 P/Share
|
|
Jul 09
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,000
+11.68%
|
$5,000
$1.6 P/Share
|
|
Jul 01
2025
|
Kenneth A. Stauderman Chief Scientific Officer |
BUY
Open market or private purchase
|
Indirect |
1,000
+50.0%
|
$1,000
$1.85 P/Share
|
|
Jun 26
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
4,500
+12.06%
|
$4,500
$1.44 P/Share
|
|
Jun 26
2025
|
Stephen Bardin Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,000
+40.0%
|
$2,000
$1.5 P/Share
|
|
Jun 11
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,000
+15.0%
|
$5,000
$1.85 P/Share
|
|
Jun 06
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,000
+17.65%
|
$5,000
$1.77 P/Share
|
|
Jun 05
2025
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,100
+21.77%
|
$5,100
$1.7 P/Share
|
|
May 30
2025
|
Stephen Bardin Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+2.38%
|
$1,000
$1.69 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 452K shares |
|---|---|
| Exercise of conversion of derivative security | 11.8K shares |
| Open market or private sale | 1K shares |
|---|